Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Background Triple negative breast cancer (TNBC) is a subtype of breast cancers with poor prognosis and targeted drug therapies are limited. To develop novel and efficacious therapies for TNBC, we developed a bispecific antibody F7AK3 that recognizes both trophoblast cell surface antigen 2 (TROP2) an...
Saved in:
| Main Authors: | Jing Wang, Lin Li, Huicheng Liu, Lili Bai, Liu Huang, Na Ning, Yijia Li, Xuejiao Dong, Qiuyang Du, Minghui Xia, Yufei Chen, Likun Zhao, Yanhu Li, Qingwu Meng, Yaqi Duan, Jie Ming, Andy Qingan Yuan, Xiang-Ping Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e003468.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
by: S. M. Greiner, et al.
Published: (2025-07-01) -
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
by: Melanie Märklin, et al.
Published: (2022-03-01) -
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting
by: V. Tomarchio, et al.
Published: (2025-04-01) -
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
by: Methi Wathikthinnakon, et al.
Published: (2022-04-01) -
The state of the art of bispecific antibodies for treating human malignancies
by: Shuhang Wang, et al.
Published: (2021-08-01)